Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19

Blood. 2022 Nov 3;140(18):1993-1997. doi: 10.1182/blood.2022018052.


Two Letters to Blood address the risks of COVID-19 in populations with precursors of hematological disease. In the first article, Miller and colleagues report on whether clonal hematopoiesis of intermediate potential (CHIP) is associated with adverse outcomes with COVID-19, finding no association between CHIP and 28-day mortality while providing data indirectly linking IL-6 signaling and patient outcomes. In the second article, Ho and colleagues investigate the outcomes of patients with monoclonal gammopathy of undetermined significance (MGUS) with COVID-19, reporting that one-fourth had a severe infection and that on multivariable analysis, adverse outcomes are more likely if immunoparesis is present.

MeSH terms

  • COVID-19*
  • Clonal Evolution
  • Clonal Hematopoiesis*
  • Hematopoiesis
  • Humans
  • Mutation